Sarcoma Foundation of America

Registration for the Marine Corps Marathon is open! Join the RTCS Marathon Team at the #MarineCorpsMarathon on October 25 in Arlington, VA! SFA is a proud charity partner of the 2026 Marine Corps Marathon. Run with us to raise awareness and funds for #sarcoma research. Every step supports the Sarcoma Foundation of America's mission to #CureSarcoma. If you are interested in joining our race team, find more information here: buff.ly/Q1fwPfZ Can’t run? Share this with friends or family who might want to take on the challenge! No Federal or Marine Corps Endorsement Implied.

Join our Advocacy Weekend Information Session next week on 3/24 to learn more about Advocacy Weekend in Washington, D.C. this July. During this session, you’ll hear what to expect during the 3-day event and how advocating, sharing your story, and connecting with lawmakers can help bring greater awareness, funding, and progress for sarcoma research and patient care. Register: buff.ly/18iqJvP   #sarcoma #curesarcoma #sarcomaadvocacy #advocacyweekend

Soft tissue sarcoma (STS) is a rare and challenging cancer, and finding effective treatments has been an ongoing area of research. A new clinical trial published in Clinical Cancer Research tested a combination of doxorubicin and durvalumab in patients with advanced STS: What they found:  - 31.7% of patients had tumors shrink (response rate) - 82.9% achieved disease control - 7.6 month median progression-free survival - 23.8 month median overall survival The researchers also identified biological markers in the tumors that may help predict which patients are most likely to benefit. This kind of research moves us closer to matching the right therapy to the right patient.   While further studies are needed, these results are a meaningful step forward for patients and families affected by this disease. #SoftTissueSarcoma #CancerResearch #Immunotherapy #RareCancer #ClinicalTrials #Oncology

National Adolescent and Young Adult (AYA) Week is April 5–11. Your story has the power to inspire, connect, and bring hope to someone else facing sarcoma. We invite you to share your journey and be featured on the Patient Stories page of our website. By telling your story, you help others feel less alone and remind our community that there is understanding, support, and a community standing beside them. Submit your story: buff.ly/7khkFop #sarcoma #curesarcoma

On this episode, we’re joined by Simone Cheatham, a member of the Race to Cure Sarcoma Chicago Committee. Simone became actively involved after her late father, Hardin, was diagnosed with sarcoma after already being diagnosed with breast cancer. Simone shares what it was like to support her father as a care partner alongside her mother while navigating a rare cancer diagnosis. Shortly after his diagnosis, Simone herself was diagnosed with Hodgkin’s lymphoma. She reflects on the stark differences between her own treatment options and those available to her father, and why advocacy and research in the sarcoma space are so critical. Listen wherever you get podcasts! #sarcoma #curesarcoma #sarcomastories #carepartner

Join us for Part 2 of our "Live with the Experts" series on circulating tumor DNA (ctDNA) in sarcoma on Wednesday, March 25, 2026, at 1:00 PM ET. Building on our first session, An Introduction to ctDNA in Sarcoma, this webinar takes the conversation a step further and highlights new research, practical considerations, and the real-world questions patients and clinicians are navigating today. Register: buff.ly/OOjuWVD #sarcoma #curesarcoma #sarcomaeducation #ctDNA

Your voice can help drive change for the sarcoma community. Join our upcoming information session to learn more about Advocacy Weekend in Washington, D.C. this July. During this session, you’ll hear what to expect during the 3-day event and how sharing your story and speaking up can help advance sarcoma research and improve care for patients and families. Register: buff.ly/18iqJvP #sarcoma #curesarcoma #sarcomaadvocacy #advocacyweekend

The March Sarcoma Spotlight newsletter is here! This issue features updates on upcoming Race to Cure Sarcoma events, information about upcoming webinars, SFA resources, and more! Read the March newsletter to stay up to date on the latest research and community news. Read here: buff.ly/xqV3QGG #curesarcoma #sarcoma #sarcomanews #sfanews

Katie participates in RTCS Austin in honor of her mother. Before I ever signed up for a race, I walked beside my mother through the fight of her life. The Sarcoma Foundation of America Race for the Cure in Austin is more than an event to me — it is a tribute to my mother, Donna. In 2018, she was diagnosed with an atypical fibrohistocytic neoplasm with necrosis — a rare cancer that would quietly change the course of our lives. After treatment, she was declared cancer-free. We were told there was only a 0.01% chance it would return after five years of remission. But in April 2023, that unlikely became our reality. Donna was diagnosed with high-grade (G-3), stage 4 sarcoma in her lungs, and the fight became urgent. Because of the rarity of her recurrence, she was accepted into a clinical rial in Los Angeles, California. When heart complications began, she was transferred to another clinical trial in Texas, allowing her to continue fighting while being closer to home. In January 2025, she reached 90 days of remission — a milestone that gave us hope. However, the battle ultimately proved too much for her earthly body. On March 4, 2025, she went to be with her Lord and Savior. To honor her fight, I joined the committee with SFA to help bring the Race for the Cure to Austin. Walking this race alongside my family and friends is how I carry her forward. Sarcoma may have altered her story, but it did not define my mother — her courage did. Every step I take is for her, for the love she poured into our family, and for the hope that continued research and awareness will change the future for another family facing this diagnosis. Join Katie and others impacted by sarcoma at RTCS Austin on March 21! Register here: buff.ly/3qrYPjF #RTCSAustin #sarcoma #curesarcoma

Cancer in children is NOT the same as cancer in adults. That's why new guidelines specifically focused on pediatric cancer are so important. The National Comprehensive Cancer Network (NCCN) just published new guidelines for pediatric rhabdomyosarcoma, the most common soft tissue sarcoma in children, helping doctors across the country provide the best possible care to some of their youngest patients. Read the full news release: buff.ly/feLgaIZ #ChildhoodCancer #PediatricOncology #NCCN

At Race to Cure Sarcoma events, we come together to honor every life touched by sarcoma and to turn remembrance into action. Every participant, every team, and every dollar raised moves us closer to new treatments and better outcomes. Join a race near you and help drive progress. #sarcoma #curesarcoma #RTCS

New study on drug combination for advanced sarcoma Researchers tested cabozantinib plus temozolomide in 72 patients with advanced soft tissue sarcoma who had limited treatment options. What they found: -74% of leiomyosarcoma patients had no disease progression at 12 weeks -Side effects were manageable with no new safety concerns -48% of leiomyosarcoma patients and 77% of other sarcoma patients had died by study end due to disease progression More research is needed, but these early results offer hope for patients who need new treatment options. Read the full study here: thelancet.com/journals/lanon… #SarcomaResearch #ClinicalTrial #Oncology #MedicalResearch

Compassionate Care Award nominations are closing soon! Nominate a nurse, community health worker, or social worker for their meaningful contributions to patient care, support, and education. If you know a navigator who has made a positive impact on patients and families affected by sarcoma, submit a nomination by March 11. The selected honoree will be recognized at the 2026 Stand Up to Sarcoma Gala in New York City on October 6, 2026. Learn more about the award and submit a nomination: buff.ly/Y0vrF85 #sarcoma #curesarcoma #standuptosarcomagala

Today is Rare Disease Day. At any given time, more than 250,000 people are living with sarcoma. This community is vast, yet “rare” still too often means delayed diagnosis, limited treatment options, and too little research funding. Rare should never mean overlooked. Behind every diagnosis is a person. A family navigating uncertainty. A community that cannot wait. SFA stands with the rare disease community today and every day, committed to a future where no one dies from sarcoma. Support SFA: buff.ly/C5Olnjy #sarcoma #curesarcoma #rarediseaseday

No one should have to navigate sarcoma alone. At an RTCS event, whether you attend as a volunteer, participant, or survivor, you will find a community of people whose lives have been touched by sarcoma. It is a space where stories are shared, support is offered, and hope is strengthened through being together. Find a race near you and experience the power of connecting with others affected by sarcoma. Together, we move closer to a future where no one dies from this disease. #curesarcoma #sarcoma #RTCS

This Saturday is Rare Disease Day, a day to remember that behind every rare diagnosis is a person, a family, and a life forever changed. Rare may describe the numbers, but it does not define the strength, resilience, and hope of people like Angela. The sarcoma community is not a statistic. It is made up of individuals who show up for one another, who advocate for better treatments, and who believe in a future with improved outcomes for everyone affected by this disease. We stand with the sarcoma community, honoring every story, amplifying every voice, and working toward a world where no one dies from sarcoma. Read Angela's full story: buff.ly/U3ihaoa #sarcoma #curesarcoma #rarediseaseday

SFA funds translational science that moves discoveries from lab to patients  Rare cancers like sarcoma are often overlooked by major funders, but that doesn’t make them less urgent. The Sarcoma Foundation of America bridges the gap between lab discoveries and real treatments for patients.  By providing seed funding for translational science, SFA helps researchers take bold, high-risk ideas from concept to discovery. This turns promising science into the preliminary data that opens doors to federal funding and, ultimately, better therapies for patients who urgently need new options.  #SarcomaResearch #RareCancer #TranslationalScience #RareDiseasesDay

Breakthroughs in rare cancers start with research funding. Support from SFA enabled Dr. Karen Pollok, PhD, to test a promising combination therapy for osteosarcoma that has spread or no longer responds to standard treatments. Because these drugs are already used in other cancers, this research could accelerate safer, more effective treatments. Investing in rare disease research today makes better treatments possible. We are proud to support researchers like Dr. Pollok who dedicate their careers to turning discovery into progress. Help us fund the next breakthrough: buff.ly/XM8AXSR

Sarcoma represents about 1% of adult cancers and, like many rare cancers, faces delayed diagnoses, limited treatment options, and less research funding. Rare cancers account for nearly 25% of all diagnoses but receive far less investment. At Sarcoma Foundation of America, we’re working to change that by funding research, supporting patients and families, and advocating for better outcomes. Together, we can close the gap and build a future where no one dies from sarcoma. Support our work: buff.ly/C5Olnjy

RTCS Austin is just one month away! Now is the perfect time to start or join a team and walk or run in honor of someone affected by sarcoma. Your participation helps improve outcomes for people diagnosed with sarcoma. Every step, every dollar, and every team makes a real difference. Register here: buff.ly/rlJb9hi #sarcoma #curesarcoma #RTCSAustin